Drugs / 2,2-dimethylbutyrate
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01601340 Comparator | Jul 2012 → Nov 2013 | sickle cell disease | HemaQuest Pharmaceuticals Inc. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2,2-dimethylbutyrate | “This placebo-controlled phase II study evaluated the pharmacodynamics, efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), a fetal globin gene-inducing short-chain fatty...” PMID 24677033 ↗ Apr 2014 |
| Known as | HQK-1001 | “This placebo-controlled phase II study evaluated the pharmacodynamics, efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), a fetal globin gene-inducing short-chain fatty...” PMID 24677033 ↗ Apr 2014 |
| Action | Activate | “fetal globin gene-inducing” PMID 24677033 ↗ Apr 2014 |
| Modality | Small molecule | “fetal globin gene-inducing short-chain fatty acid derivative” PMID 24677033 ↗ Apr 2014 |
| Route | Oral | “administered orally” PMID 24677033 ↗ Apr 2014 |